Skip to content
The Policy VaultThe Policy Vault

Firazyr — Blue Cross Blue Shield of Texas

hereditary angioedema (HAE) for acute treatment

Initial criteria

  • 1. ONE of the following: (A) continuation of therapy and prescriber states the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed OR (B) ALL plan-specific initial approval criteria (details not fully included in visible text segment)